Christopher Ogden - 13 Jun 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Financial Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Issuer symbol
CTMX
Transactions as of
13 Jun 2025
Net transactions value
-$33,381
Form type
4
Filing time
17 Jun 2025, 16:11:18 UTC
Previous filing
20 Mar 2025
Next filing
30 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ogden Christopher Chief Financial Officer C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO /s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden 17 Jun 2025 0001914523

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Sale $4,841 -1,641 -0.82% $2.95 199,385 13 Jun 2025 Direct F1, F2
transaction CTMX Common Stock Options Exercise $0 +37,500 +19% $0.000000 236,885 13 Jun 2025 Direct F2, F3
transaction CTMX Common Stock Sale $28,540 -10,614 -4.5% $2.69 226,271 16 Jun 2025 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Performance Stock Units Options Exercise $0 -37,500 -100% $0.000000 0 13 Jun 2025 Common Stock 37,500 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2 Includes 149,987 RSUs.
F3 This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023.
F4 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
F5 Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.